About Tempero Bio
Tempero Bio is a company based in Oakland (United States) founded in 2020 by Ricardo Dolmetsch. Tempero Bio has raised $70 million across 1 funding round from investors including Khosla Ventures, 8VC and Aditum Bio. Tempero Bio offers products and services including TMP-301. Tempero Bio operates in a competitive market with competitors including IgGenix, Mithradote Bio, Globin Solutions, metaLead Therapeutics and Sobrera, among others.
- Headquarter Oakland, United States
- Founders Ricardo Dolmetsch
- SectorsHealthcare
- Email••••••••
- Phone•••• ••••
- Website temperobio.com
- Social LinkedIn X
- Total Equity Funding$70 M (USD)
in 1 rounds
- Latest Funding Round$70 M (USD), Series B
Mar 24, 2025
- InvestorsKhosla Ventures
& 2 more
Products & Services of Tempero Bio
Tempero Bio offers a comprehensive portfolio of products and services, including TMP-301.
Drug for treating substance use disorders like CUD and AUD
Funding Insights of Tempero Bio
Tempero Bio has successfully raised a total of $70M through 1 strategic funding round. The most recent funding activity was a Series B round of $70 million completed in March 2025. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
- Total Funding $70.0M
- Total Rounds 1
- Last Round Series B — $70.0M
- First Round $70.0M
(24 Mar 2025)
- Investors Count 3
All 1 funding rounds of Tempero Bio with amounts and investors; the two latest post-money valuations are shown, the rest are part of the premium plan.
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| 24 Mar 2025 | $70.0M | Series B | – | 8VC |
3 investors in total: 3 institutional.
Investors in Tempero Bio
Tempero Bio has secured backing from 3 investors, including venture fund investors. Prominent investors backing the company include Khosla Ventures, 8VC and Aditum Bio.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
Venture capital firm investing in technology, life sciences, and related sectors. | – | 8vc.com | - | |
Early-stage startups are funded by this venture capital firm. | 2004 | khoslaventures.com | Menlo Park, United States | |
Serves as a CRO specializing in Phase II clinical trials. | 2019 | aditumbio.com | Oakland, United States |
Investor details for Tempero Bio
The complete investor list, round-by-round participation and investor portfolios require an active premium plan.
- Complete investor list
- Round participation
- Investor portfolios
- Co-investor network
Verified entity values are shown only after access is granted.
People of Tempero Bio
1 people are tracked at Tempero Bio (1 in leadership).
| Name | Role | Group |
|---|---|---|
Ricardo Dolmetsch | Founder | Leadership |
Complete people profiles for Tempero Bio
Full employee and board profiles, team structure, tenure and professional contact details require an active premium plan.
- Full employee list
- Team structure
- Board tenure
- Professional contacts
Verified entity values are shown only after access is granted.
Timeline of Tempero Bio
2 dated milestones of Tempero Bio across 5 years, from founding to its latest funding, stage changes and deals.
- Founded Tempero Bio is founded.
- Funding First funding round of $70.0M.
Competitors of Tempero Bio
Tempero Bio operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as IgGenix, Mithradote Bio, Globin Solutions, metaLead Therapeutics and Sobrera, among others.
| Company Name | Domain | Founded | HQ Location | Total funding | Employees | Description |
|---|---|---|---|---|---|---|
| iggenix.com | 2019 | San Francisco, United States | $75.0M | – | Therapeutic solutions for food allergies are developed via antibody platforms. | |
| mithradote.com | 2023 | San Diego, United States | $1.0M | – | Medication is provided to prevent drug-facilitated sexual assault. | |
| globinsolutions.com | 2017 | Pittsburgh, United States | $5.0M | – | Antidotal therapies for human poisonings are developed using neuroglobin technology. | |
| metaleadtherapeutics.tcc.mode | 2022 | Zurich, Switzerland | $170,018 | – | Next-generation medications against metal poisoning are developed. | |
| sobrera.com | 2019 | Gothenburg, Sweden | – | – | Drugs for alcohol use disorders are developed by Sobrera. | |
| kaivallabs.com | 2019 | Palm Bay, United States | – | – | Develops innovative technologies for nicotine addiction treatment. | |
| junhemeng.tcc.mode | 2020 | Hangzhou, China | – | – | Recombinant protein drugs are developed for toxicity and metabolic diseases. | |
| alarpharm.com | 2016 | Taichung, Taiwan | – | – | Drugs for opioid use disorder and depressive disorder are developed. | |
| aphiotx.com | 2021 | Calgary, Canada | – | – | Therapeutics targeting pannexin-1 for opioid use disorder are developed. |
Detailed competitors of Tempero Bio
The full competitor set, operating metrics and side-by-side benchmarks require an active premium plan.
- Full competitor set
- Operating metrics
- Benchmarks
- Competitive positioning
Verified entity values are shown only after access is granted.
Latest news on Tempero Bio
Complete news archive for Tempero Bio
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Similar companies to Tempero Bio
10 companies that operate in the same segment as Tempero Bio (Toxicology), ranked by their profile score on The Company Check.
| Company | Description | Founded | Location | Total funding | Revenue | Employees |
|---|---|---|---|---|---|---|
Therapeutic solutions for food allergies are developed via antibody platforms. | 2019 | San Francisco, California, United States | USD 75 M | – | – | |
Drug delivery solutions via single-walled carbon nanotubes are offered. | 2008 | Houston, Texas, United States | USD 2.5 M | USD 5.07 M | 9 | |
Non-invasive drug testing technology is developed using fingerprints. | 2007 | Cambridge, Cambridgeshire, United Kingdom | USD 25.71 M | – | – | |
Provides toxicology, chemistry, and consultancy services for agrochemical industries. | 2020 | Vapi, Gujarat, India | – | – | – | |
Instruments for rapid human DNA identification are developed. | 2006 | Pleasanton, California, United States | USD 92.06 M | USD 22.5 B | 78 | |
Oral therapies for snake bite treatment are developed. | 2015 | Corte Madera, California, United States | USD 16.48 M | – | – | |
Quantitative urine drug testing is provided for patient monitoring. | 2011 | San Diego, California, United States | – | – | 358 | |
Point-of-care platforms for heavy metal toxicity diagnostics are developed. | 1968 | Billerica, Massachusetts, United States | USD 34 M | – | – | |
Real-time trace gas analysis solutions are delivered using SIFT-MS technology. | 2002 | Christchurch, New Zealand | USD 11.9 M | USD 23.52 M | – | |
Fentanyl test strips are supplied for harm reduction efforts. | 2005 | Los Angeles, California, United States | – | – | – |
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Frequently Asked Questions about Tempero Bio
Tempero Bio was founded in 2020 and raised its 1st funding round 5 years after it was founded.
Tempero Bio is headquartered in Oakland, United States. It is registered at Oakland, California, United States.
Tempero Bio is a funded company, having raised a total of $70M across 1 funding round to date. The company's 1st funding round was a Series B of $70M, raised on Mar 24, 2025.
Tempero Bio was founded in 2020 and is based in Oakland, United States, within the biotechnology sector focused on substance use disorders. Treatments for opioid use disorders and related conditions are developed by the company. The lead candidate, TMP-301, is investigated as an orally available metabotropic glutamate receptor 5 negative allosteric modulator for cocaine use disorder and alcohol use disorder. Operations center on advancing these therapeutics through clinical investigation.
Tempero Bio's top competitors include IgGenix, Mithradote Bio and Globin Solutions.
Tempero Bio offers TMP-301.
Tempero Bio has 3 investors. Key investors include Khosla Ventures, 8VC, and Aditum Bio.